trending Market Intelligence /marketintelligence/en/news-insights/trending/tB8dgoRxLrZPSvM71SD2UQ2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Alexion, Zealand Pharma sign deal to discover peptide therapies

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Alexion, Zealand Pharma sign deal to discover peptide therapies

Alexion Pharmaceuticals Inc. and Zealand Pharma A/S will collaborate to discover and develop peptide-based therapies that target diseases related to the body's complement system.

Under the agreement, Boston-based Alexion will pay $25 million up front and make a $15 million equity investment in Denmark-based Zealand.

Alexion will have exclusive worldwide licenses and commercial rights for up to four targets within the complement pathway. The complement system is a part of the immune system which enhances the ability of antibodies to fight damaged cells. The system is thought to play a role in many diseases.

Zealand Pharma will lead discovery and research activities in the preclinical stage, while Alexion will oversee development from filing the investigational new drug application and phase 1 trials.

Zealand Pharma may receive up to $115 million in development-related milestones, and up to $495 million in sales-related milestones and potential royalty for the lead target.

Alexion has the option to select the remaining three target therapies for $15 million each, plus potential development and sales-related milestone payments along with royalties at a lower price than the lead candidate.